Nuvation Bio Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Nuvation Bio Inc. (NUVB) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $2.52 million for the 8-month period ending 2020-12-31, per its 10-K/A filed 2021-05-21.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2021-05-21
- 2020-12-31: Increase (Decrease) in Accounts Payable and Accrued Liabilities 8 month $2.52M; Increase (Decrease) in Accounts Payable and Accrued Liabilities 8 month as first filed $2.70M.
- 2020-09-30: Increase (Decrease) in Accounts Payable and Accrued Liabilities 5 month $650.03K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 5 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 8 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 8 month as first filed |
|---|---|---|---|
| 2020-12-31 | $2.52M 10-K/A · filed 2021-05-21 | $2.70M 10-K · filed 2021-03-11 | |
| 2020-09-30 | $650.03K 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |